

ActHIB [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)]

ActHIB is indicated for the prevention of invasive disease caused by *Haemophilus influenzae* type b. ActHIB vaccine is approved for use as a four dose series in infants and children 2 months through 5 years of age

IMPORTANT SAFETY INFORMATION FOR ActHIB [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)]

ActHIB is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) after a previous dose of any *Haemophilus influenzae* type b or tetanus toxoid-containing vaccine or to any component of ActHIB.

If Guillain-Barré syndrome has occurred within 6 weeks following previous vaccination with a tetanus toxoid-containing vaccine, or if adverse events have occurred in temporal relation to receipt of tetanus toxoid-containing vaccine, the decision to give ActHIB should be based on careful consideration of the potential benefits and risks.

Syncope (fainting) has been reported following vaccination with ActHIB. Procedures should be in place to avoid injury from fainting.

The most common local and systemic adverse reactions to ActHIB in children 15-20 months of age include tenderness, induration, and swelling at the injection site; irritability, drowsiness, and anorexia. The most common systemic adverse reactions for children 2-16 months of age include fussiness/irritability, inconsolable crying, and decreased activity/lethargy. Other adverse reactions may occur. Vaccination with ActHIB may not protect all individuals.

Please see full [Prescribing Information](#) for ActHIB

Based on ActHIB Prescribing Information - Dated 07/2022